MX348337B - Peptido derivado de lactoferrina humana para usarse como agente de enmascaramiento de antigenos. - Google Patents

Peptido derivado de lactoferrina humana para usarse como agente de enmascaramiento de antigenos.

Info

Publication number
MX348337B
MX348337B MX2013005820A MX2013005820A MX348337B MX 348337 B MX348337 B MX 348337B MX 2013005820 A MX2013005820 A MX 2013005820A MX 2013005820 A MX2013005820 A MX 2013005820A MX 348337 B MX348337 B MX 348337B
Authority
MX
Mexico
Prior art keywords
derived peptide
human lactoferrin
masking agent
active substance
lactoferrin derived
Prior art date
Application number
MX2013005820A
Other languages
English (en)
Other versions
MX2013005820A (es
Inventor
Windhab Norbert
Hartwig Benedikt
Tome Alcalde Juan
Del Pilar Ansuategui Panzano Maria
Javier Vara Carrera Matías
Original Assignee
Evonik Roehm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Roehm Gmbh filed Critical Evonik Roehm Gmbh
Publication of MX2013005820A publication Critical patent/MX2013005820A/es
Publication of MX348337B publication Critical patent/MX348337B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a un péptido derivado de lactoferrina humana para usarse como un agente de enmascaramiento de antígenos en la producción de una composición farmacéutica para el suministro de una sustancia biológicamente activa en un organismo mamífero, en donde la sustancia biológicamente activa es capaz de inducir una respuesta inmune no deseada por el organismo mamífero, en donde la composición farmacéutica comprende un agregado supramolecular de la sustancia biológicamente activa y el péptido derivado de lactoferrina humana, con el efecto de que después del suministro de la composición farmacéutica al organismo mamífero, no hay o sólo hay una inducción reducida de la respuesta inmune no deseada contra la sustancia biológicamente activa.
MX2013005820A 2010-11-26 2010-11-26 Peptido derivado de lactoferrina humana para usarse como agente de enmascaramiento de antigenos. MX348337B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2010/068302 WO2012069089A1 (en) 2010-11-26 2010-11-26 Human lactoferrin derived peptide for use as an antigen masking agent

Publications (2)

Publication Number Publication Date
MX2013005820A MX2013005820A (es) 2013-07-12
MX348337B true MX348337B (es) 2017-06-07

Family

ID=43837881

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013005820A MX348337B (es) 2010-11-26 2010-11-26 Peptido derivado de lactoferrina humana para usarse como agente de enmascaramiento de antigenos.

Country Status (16)

Country Link
US (1) US9724422B2 (es)
EP (1) EP2643344B1 (es)
JP (1) JP6073239B2 (es)
KR (1) KR101765364B1 (es)
CN (1) CN103906760B (es)
AU (1) AU2010364538B2 (es)
BR (1) BR112013012811B8 (es)
CA (1) CA2818951C (es)
ES (1) ES2627960T3 (es)
HU (1) HUE033501T2 (es)
IL (1) IL226198B (es)
MX (1) MX348337B (es)
PL (1) PL2643344T3 (es)
RU (1) RU2573422C2 (es)
SI (1) SI2643344T1 (es)
WO (1) WO2012069089A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3148515B1 (en) 2014-05-28 2019-12-04 Evonik Degussa GmbH Nanoparticle
JP2019508036A (ja) 2016-02-16 2019-03-28 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 免疫療法組成物及び方法
DE102016008601B4 (de) 2016-07-14 2019-05-23 Giesecke+Devrient Currency Technology Gmbh Sicherheitselement mit reversibel veränderbarem Farbbereich
WO2018160791A1 (en) 2017-03-03 2018-09-07 Massachusetts Institute Of Technology Antimicrobial constructs and uses thereof
CN107226860B (zh) * 2017-07-06 2020-04-10 浙江辉肽生命健康科技有限公司 一种生物活性多肽skhssldcvl及其制备方法和应用
EP3790534B1 (en) 2018-05-08 2023-08-30 Evonik Operations GmbH Nanoparticle comprising a bio-resorbable polyester, a hydrophilic polymer and an acylated human lactoferrin-derived peptide

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6066469A (en) * 1990-03-08 2000-05-23 Ferro Dynamics, Inc. Cloning, expression, and uses of human lactoferrin
US5977337A (en) 1997-06-03 1999-11-02 Connaught Laboratories Limited Lactoferrin receptor genes of Moraxella
JP3681982B2 (ja) 1998-07-15 2005-08-10 サムヤン ジェネックス コーポレイション 酵母からラクトフェリンポリペプチドを大量生産する方法及びそれに有用な微生物菌株
JP2000045182A (ja) 1998-07-23 2000-02-15 Peptide Science:Kk 抗菌性繊維および繊維・皮革用抗菌加工剤
US20070259007A1 (en) * 1999-10-19 2007-11-08 Kruzel Marian L Lactoferrin: an adjuvant for vaccines
RU2165769C1 (ru) * 2000-07-13 2001-04-27 Якубовская Раиса Ивановна Антибактериальный, антиоксидантный, иммуномодулирующий и антиканцерогенный препарат и способ его применения
ES2306902T3 (es) * 2002-10-25 2008-11-16 Techlab, Inc. Panel de diagnostico ibd-first chek para la enfermedad inflamatoria del intestino y el sindrome del colon irritable.
WO2004052305A2 (en) 2002-12-10 2004-06-24 Agennix Incorporated Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
DE102005051366A1 (de) 2005-10-25 2007-04-26 Degussa Gmbh Drug Delivery Systeme
ATE501169T1 (de) 2005-12-30 2011-03-15 Evonik Roehm Gmbh Lactoferrin-peptide, geeignet als in die zelle eindringende peptide

Also Published As

Publication number Publication date
HK1196379A1 (zh) 2014-12-12
CN103906760B (zh) 2017-02-22
CA2818951C (en) 2018-03-13
RU2573422C2 (ru) 2016-01-20
MX2013005820A (es) 2013-07-12
BR112013012811B8 (pt) 2022-07-05
AU2010364538B2 (en) 2016-04-14
JP2014501723A (ja) 2014-01-23
BR112013012811A2 (pt) 2016-09-13
SI2643344T1 (sl) 2017-07-31
PL2643344T3 (pl) 2017-09-29
AU2010364538A1 (en) 2013-07-11
BR112013012811B1 (pt) 2021-07-06
KR20130119955A (ko) 2013-11-01
JP6073239B2 (ja) 2017-02-01
ES2627960T3 (es) 2017-08-01
IL226198B (en) 2019-01-31
WO2012069089A1 (en) 2012-05-31
HUE033501T2 (en) 2017-12-28
EP2643344B1 (en) 2017-03-22
KR101765364B1 (ko) 2017-08-08
RU2013128884A (ru) 2015-01-10
US9724422B2 (en) 2017-08-08
EP2643344A1 (en) 2013-10-02
CN103906760A (zh) 2014-07-02
CA2818951A1 (en) 2012-05-31
IL226198A0 (en) 2013-07-31
US20130302342A1 (en) 2013-11-14

Similar Documents

Publication Publication Date Title
WO2014145159A3 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
TN2012000335A1 (en) Antibody formulation and therapeutic regimens
CY1119192T1 (el) Μεθοδος κρυσταλλωσης και βιοδιαθεσιμοτητα
MX2012010114A (es) Formulaciones concentradas de proteina y usos de las mismas.
EA201490004A1 (ru) Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей
GB201201314D0 (en) Composition
MX2012007806A (es) Composiciones farmaceuticas para administracion oral de peptidos de insulina.
IN2012MN02591A (es)
MX349004B (es) Nuevos compuestos.
MX340985B (es) Compuestos de n-heteroarilo.
PH12015500713B1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
LT2013015A (lt) Farmacinės kompozicijos
UA112549C2 (uk) Частинки на основі поліакрилату, що містять активну сполуку
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
GEAP201813377A (en) New therapeutical composition containing apomorphine as active ingredient
MX348337B (es) Peptido derivado de lactoferrina humana para usarse como agente de enmascaramiento de antigenos.
MX2014004953A (es) Ligadores basados en tirosina para la conexion desprendible de peptidos.
TN2014000498A1 (en) Pharmaceutical formulation
EA201301264A1 (ru) Способ получения неорганического материала в виде частиц
SG178596A1 (en) Methods of treatment using anti-oxidized ldl antibodies
IN2013MU03847A (es)
GEP20156332B (en) Pyrazoles as crth2 antagonists
MX2013010367A (es) Composiciones y metodos para la terapia y diagnostico de influenza.
MX2013009529A (es) Tratamiento de enfermedad de crohn con fistulas.
CL2013000771A1 (es) Formulacion acuosa estable que comprende polipeptido del factor estimulante de colonias de granulocitos bovino (bg-csf); liofilizado de la preparacion; proceso para preparar la formulación; uso para tratar infección en un animal.

Legal Events

Date Code Title Description
FG Grant or registration